Cargando…
Home infusion with Elosulfase alpha (Vimizim(R)) in a UK Paediatric setting
Enzyme replacement therapy is the only available treatment for Mucopolysaccharidosis type IVA (MPS IVA, Morquio syndrome). The treatment is lengthy and invasive involving weekly intravenous infusions of 4–5 h. This can cause significant disruption to normal family life so the provision of a safe and...
Autores principales: | Finnigan, Niamh, Roberts, Jane, Mercer, Jean, Jones, Simon A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675729/ https://www.ncbi.nlm.nih.gov/pubmed/29159073 http://dx.doi.org/10.1016/j.ymgmr.2017.10.012 |
Ejemplares similares
-
Role of elosulfase alfa in mucopolysaccharidosis IVA
por: Regier, Debra S, et al.
Publicado: (2016) -
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome
por: Lee, Chung-Lin, et al.
Publicado: (2022) -
Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y
por: Jones, Simon A., et al.
Publicado: (2015) -
Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome
por: Qi, Yulan, et al.
Publicado: (2014) -
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome
por: Hendriksz, Christian J., et al.
Publicado: (2016)